CliffBio
biologic

Alprolix

Coagulation Factor IX (Recombinant), Fc Fusion Protein

Loss of exclusivityMarch 2026projected — 12-year biologic exclusivity estimate
CompanyBioverativ →See this company's full patent-cliff portfolio

Drug detail

Brand nameAlprolix
Active ingredientCoagulation Factor IX (Recombinant), Fc Fusion Protein
Strength500IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2014
Marketing statusRx

More from Bioverativ

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Alprolix patent cliff — loss of exclusivity March 2026 | CliffBio